What is Ezetimibe?

Hyperlipidemia is one of the risk factors of coronary heart disease, drugs in the clinical treatment of hyperlipidemia mainly includes cholesterol synthesis inhibitors (statins), benzene oxygen acids (e.g., Betty class), bile acid rock mixture (e.g., cholestyramine) and other (e.g., nicotinic acid analogues), etc.

Ezetimibe  is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the smallintestine. It may be used alone (marketed as Zetia or Ezetrol), when other cholesterol-lowering medications are not tolerated, or together with statins (e.g., ezetimibe/simvastatin, marketed as Vytorin and Inegy) when statins alone do not control cholesterol. Ezetimibe is developed by Merck and Schering Plough - new cholesterol absorption inhibitor, in October 2002, approved by the FDA, commodity called Zetia (Zetia).